Evotec Multiple Sclerosis Drug Studies Receive ā‚¬5 Million in New Funding

Funding for continued research and development into understanding, treating, and eventually curing Multiple Sclerosis continues to accelerate. Evotec AG, aĀ German company that specializes in providing drug discovery resources to pharmaceutical and biotech companies, and learning institutions, has just announced the launch of its line-up of groundbreaking studies intoĀ MSĀ — an…

RRMS Treatment from Antisense Highly Effective in Clinical Trials

For the first time, an antisense oligonucleotide has been shown to be effective in treating relapse-remitting multiple sclerosis. A phase 2a clinical trial of Antisense Therapeutics Limited’s ATL1102, a CD49d antisense drug, showed that the treatment quickly reduced brain lesions in RRMS patients following the start of therapy.

MuckFest MS Los Angeles 5K Mud Fun Run on October 25

MuckFestĀ® MS runners getting down and dirty for a cause. One of the more engaging ways to campaign for awareness and fundraising for a disease is hosting a sporting event. Be it a marathon, weight lifting, biking, or even ziplining, adding an element of fun in supporting a serious…

Teva, Active Biotech Present Positive Findings for RRMS Experimental Therapy Laquinimod

During the 30th Congress of the European Committee for Research and Treatment in Multiple Sclerosis (ECTRIMS) last week in Boston, Teva Pharmaceutical Industries Ltd. (NYSE:TEVA), together with Active Biotech (NASDAQ OMX NORDIC:ACTI), presented new follow-up data evaluating the clinical safety of laquinimod in patients with relapsing-remitting multiple sclerosis (RRMS)…

Novartis Presents Impressive Gilenya Updates at MSBoston 2014

This past Wednesday, September 10th, the largest, most anticipated multiple sclerosis (MS) convention — the 6th Joint ACTRIMS-ECTRIMS Triennial Meeting, MSBoston 2014 — kicked off with a whopping 8,000 registered attendees, all eager to learn more about the latest developments in MS. One of the highlights of the event…

Receptos to Present Data on RMS Treatment Trial at MSBoston 2014

Biopharmaceutical companyĀ Receptos, Inc. announced that they will review data from the phase 2 portion of theĀ RADIANCE trial,Ā the company’s phase 2 / 3 study testing RPC1063 in the treatment ofĀ Relapsing Multiple Sclerosis (RMS).Ā The data is being presented at theĀ largest meeting dedicated to multiple sclerosis…

Multiple Sclerosis Trial for Lisinopril Granted $1.4 Million in New Funding From NCATS

Transparency Life Sciences, LLCĀ (TLS), the first clinical-stage drugĀ development company based on open innovation in the world, recentlyĀ receivedĀ a $1.4 millionĀ Small Business Innovation Research (SBIR) grant intended for its phase IIa proof-of-concept study, which is assessing the utility of the ACE inhibitor lisinopril as an adjunctive treatment for patients with multiple…

Working Memory and Cognitive Reserve Linked in MS Kessler Foundation Study

Any intervention that could helpĀ multiple sclerosis patients preserve long-term memory would likely be well-received. As suggested by a recent study from the Kessler Foundation, “Working Memory Mediates the Relationship Between Intellectual Enrichment and Long-term Memory in Multiple Sclerosis: An Exploratory Analysis of Cognitive Reserve,” one…

Oceans of Hope Yacht For MS Awareness Anchored In Boston

The Oceans of Hope yacht, part of the Sailing Sclerosis Foundation project, has recently arrived in Boston after its transoceanic trip from Lisbon, the first by a crew of people with multiple sclerosis, announced the foundation through its webpage. The yacht, which started its sailing journey in…